Dahl, Dominik

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes

Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 597

Effects of Intravenous and Dietary Lipid Challenge on Intramyocellular Lipid Content and the Relation With Insulin Sensitivity in Humans

Bachmann, O. P., Dahl, D. B., Brechtel, K., Machann, J., Haap, M., Maier, T., Loviscach, M., Stumvoll, M., Claussen, C. D., Schick, F., et al. (2001) · Diabetes

Diabetes, Cardiovascular Risks, and LipoproteinsDiet, Metabolism, and Disease

Cited by 369

Lipid content in the musculature of the lower leg assessed by fat selective MRI: Intra‐ and interindividual differences and correlation with anthropometric and metabolic data

Machann, J., Bachmann, O. P., Brechtel, K., Dahl, D. B., Wietek, B., Klumpp, B., Häring, H., Claussen, C. D., Jacob, S., & Schick, F. (2003) · Journal of Magnetic Resonance Imaging

Advanced MRI Techniques and ApplicationsBody Composition Measurement Techniques

Cited by 73

Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes

Kazda, C. M., Bue-Valleskey, J. M., Chien, J., Zhang, Q., Chigutsa, E., Landschulz, W., Wullenweber, P., Haupt, A., & Dahl, D. (2023) · Diabetes Care

Diabetes Management and ResearchDiabetes and associated disorders

Cited by 56